AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03604250 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lifestyle plus prebiotic supplement
Description: Research participants will be asked to wear health monitoring devices, including a continuous glucose and heart-rate monitors. They may be prompted to perform lifestyle modifications aimed at better understanding their health parameters, based on the results obtained from the wearable devices and other tests. During the last 3 weeks of the study, research participants may be asked to take a personalized prebiotic supplement, up to once/day.
Study NCT05694624 — intervention group
Intervention type: DRUG
Intervention: Para Aminohippurate
Description: Measurements of renal plasma flow and glomerular filtration rate
Study NCT05409417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental drug
Description: Tilelizumab combined with XELOX and bevacizumab or tislelizumab combined with FOLFOX and cetuximab
Study NCT06141954 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low level laser therapy
Description: Low-level laser (light) therapy (LLLT) is a fast-growing technology used to treat a multitude of conditions that require stimulation of healing, relief of pain and inflammation, and restoration of function.
Study NCT05201157 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupressure group
Description: A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points exposed. The most preferred points ST36, LI4 and SP6 were selected from the points reported to affect lactation by reviewing the literature on the points to be compressed. Acupressure will be applied to points (bidirectional, right and left) for 2 minutes for a total of 6 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it will be moved to the other point in the symmetrical region and the application will be made without interruption. While practicing, the researcher will control the time using a digital wrist watch with a stopwatch
Study NCT05201157 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: No application will be made. The mothers in this group will fill in the Visual Similarity Scale for Fatigue twice, once between 8-12 hours post-op and once on the post-op 2nd day.
Study NCT04487613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moringa oleifera leaf
Description: 450 mg capsule
Study NCT04487613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsule
Study NCT05593783 — intervention group
Intervention type: PROCEDURE
Intervention: lithotripsy
Description: lithotripsy
Study NCT06532578 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPX101 or placebo 120mg Q2W
Description: Subcutaneous injection of CPX101 or placebo
Study NCT04934670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-Guard
Description: T-Guard will be administered intravenously inpatient over 4 hours every 2 calendar days on Days 0, 2, 4, and 6, at a dose of 4mg/m2 Body Surface Area (BSA).
Study NCT04934670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruxolitinib
Description: Ruxolitinib will be administered orally twice a day starting on Day 0 through Day 56, at a dose of 10mg. Ruxolitinib taper can be initiated starting on Day 56 for participants responding to treatment, tapering will be done according to institutional practices.
Study NCT06135519 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Mesenchymal stem cells injection
Description: Autologous Mesenchymal stem cells will be seperated from harvested fat and injected in acne scars
Study NCT06135519 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Homogenized fat injection
Description: Autologous fat will be harvested, homogenized and injected.
Study NCT06532578 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPX101 or placebo 160mg Q4W
Description: Subcutaneous injection of CPX101 or placebo
Study NCT06532578 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPX101 or placebo 160mg Q2W
Description: Subcutaneous injection of CPX101 or placebo
Study NCT06532578 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPX101 or placebo 240mg Q4W
Description: Subcutaneous injection of CPX101 or placebo
Study NCT06532578 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPX101 or placebo 240mg Q2W
Description: Subcutaneous injection of CPX101 or placebo
Study NCT06529497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racecadotril
Description: The intervention group will receive racecadotril+ORS+Zinc
Study NCT06529497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racecadotril
Description: The intervention group will receive racecadotril+ORS+Zinc
Study NCT06336070 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT program (8 weeks)
Description: Metabolic Power Training: A High Intensity Interval Training (HIIT) intervention, 3 times per week (30 min session) during 8 weeks with professional supervision and intensities adapted and modified during the intervention period.
Study NCT06336070 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MPI program (8 weeks)
Description: Muscle Power Intervention (MPI), 2 times per week (45 min session) during 8 weeks with professional supervision and intensities adapted and modified during the intervention period.
Study NCT06389812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual-task exercise traning
Description: To assess the dynamic effects of each intervention, only one session (30 mins) will be provided. The chair-based exercise session consists of three parts 5 min of active stretching exercises to warm-up, 20 mins of resistance band exercises in a sitting position (Elliott-King et al., 2019) (please see the link for detailed descriptions for seated resistance band workout) and 5 min of passive stretching exercises to cold down. The motor-cognitive dual-task group will be additionally asked to do horizontal eye movements by watching a TV screen and following a duck moving from side to side (bilateral condition) while performing strengthening exercises. The duck moves successively between left and right banks of a river at a rate of 500 ms (Brunyé et al., 2009) which was previously found to improve cognitive function
Study NCT06389812 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dual-task exercise traning
Description: To assess the dynamic effects of each intervention, only one session (30 mins) will be provided. The chair-based exercise session consists of three parts 5 min of active stretching exercises to warm-up, 20 mins of resistance band exercises in a sitting position (Elliott-King et al., 2019) (please see the link for detailed descriptions for seated resistance band workout) and 5 min of passive stretching exercises to cold down. The motor-cognitive dual-task group will be additionally asked to do horizontal eye movements by watching a TV screen and following a duck moving from side to side (bilateral condition) while performing strengthening exercises. The duck moves successively between left and right banks of a river at a rate of 500 ms (Brunyé et al., 2009) which was previously found to improve cognitive function
Study NCT06370637 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MASD Control Arm
Description: Tthe research coordinator HANS team will provide participants with a daily survey, a weekly survey, a Bristol stool scale and a 200 ml container with the specific cream for the arm assigned. Participants will be directed to apply the cream liberally after each bowel movement after cleaning the area in their usual manner. The research coordinator HANS team will review the instructions of application with the patient.
Study NCT06370637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MASD Control Arm
Description: Tthe research coordinator HANS team will provide participants with a daily survey, a weekly survey, a Bristol stool scale and a 200 ml container with the specific cream for the arm assigned. Participants will be directed to apply the cream liberally after each bowel movement after cleaning the area in their usual manner. The research coordinator HANS team will review the instructions of application with the patient.
Study NCT05255016 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PXL Platinum 330 system + Riboflavin 0.25% TE Solution
Description: Standard-of-care therapy (antifungal drops or fortified antibiotics and empiric antibiotic drops). In addition CXL + Riboflavin 0.25% TE solution.~After topical anesthesia, the surgeon or trained designee will apply topical riboflavin (1 drop every 2 min for 40 min with PESCHKE TE solution \[0.25%\], or longer as needed to assure adequate corneal penetration). At the end of this pre-treatment period, the eye will be examined at the slit lamp with the blue filter for the presence of riboflavin throughout the stroma. When sufficient corneal riboflavin penetration is confirmed, the eye will be aligned under the PXL Platinum 330 light. The correct aperture setting (3 to 12 mm) will be selected for the size of the eye and area needing to be treated (2 mm larger than the maximal ulcer diameter), and the eye will be irradiated at 18 mW/cm2, with pulsed mode (5 seconds on, 5 seconds off) for 10 min, during which time instillation of riboflavin will continue (1 drop every 2 min).
Study NCT05255016 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham CXL + Artificial Tears
Description: Standard-of-care therapy (antifungal drops or fortified antibiotics and empiric antibiotic drops). In addition, for subjects in the sham group, artificial tears (1 drop every 2 min for 40 min) will be administered. after instillation of artificial tears, the eye will be aligned under the PXL Platinum 330 light. The instrument will be kept off and the subject will be kept under the device for 10 min during which time instillation of artificial tears will be performed (1 drop every 2 min) to maintain corneal hydration. The operator will keep track of sham exposure time independently to confirm the actual duration.
Study NCT06303765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice Resource for Driving After Stroke (PReDAS)
Description: 1. Provision of written copy of PReDAS for occupational therapist to review~2. 1:1 online training session to use the PReDAS (1 hour in length)
Study NCT05011903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cross-tailored Dynamic Feedback
Description: Dynamic, technology-delivered weekly feedback on weekend diary self-reports of first-year college student behavior related to alcohol use and related sexual behaviors.
Study NCT05011903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Feedback Intervention
Description: Technology-delivered personalized feedback on first-year college student behavior related to alcohol use and related sexual behaviors.
Study NCT05011903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dynamic Feedback on General Health Behaviors
Description: Dynamic, technology-delivered weekly feedback on weekend diary self-reports of first-year college student behavior related to general health behaviors.
Study NCT06171152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide Pen Injector [Saxenda]
Description: A weight loss drug that can be taken at home. Liraglutide will be provided as an injectable pen that participants can inject in the stomach, thigh or upper arm. A member of the research team will give you instructions on how to inject liraglutide using the injectable pen and answer any questions.
Study NCT06171152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Diary
Description: Participants will be asked to maintain a medication diary of each dose of liraglutide. A member of the research team will provide a copy of this diary for participants to complete. Participants will be asked to return this medication diary to research staff at each clinic visit.
Study NCT06532838 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optimized treatment strategies
Description: The optimized strategies based on 6-hour threshold from symptom onset. For malperfused patients with symptom onset within 6 hours, central repair will be performed immediately. Additional stenting will be used in patients with persistent malperfusion. For malperfused patients with symptom onset beyond 6 hours, individualized delayed central repair according to the different types of MPS will be performed after organ function improved and the patient could tolerate central repair.
Study NCT06532838 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional treatment strategies
Description: Immediate central repair will be performed for patients with coronary and cerebral malperfusion syndrome. However, for patients with mesenteric and lower extremity malperfusion syndrome, interventional therapy will be administered through fenestration and/or stenting to ﬁrst alleviate organ ischemia. Once the patients had a resolution of organ failure, corrective open aortic repair will be performed.
Study NCT05476003 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Ultrasound-guided Bilateral superficial cervical plexus block
Description: This nerve block is typically performed in the supine or semi-sitting position, with the head turned slightly away from the side to be blocked to facilitate operator access.~Under strict aseptic condition, the linear ultrasound transducer should be placed on the lateral neck, overlying the sternocleidomastoid muscle at the level of its midpoint (approximately the level of the cricoid cartilage). Once the sternocleidomastoid muscle has been identified, the transducer is moved posteriorly until the tapering posterior edge is positioned in the middle of the screen.~Once the plexus has been identified and using In-Plane approach, the needle is passed from medial to lateral through the skin, platysma and investing layer of deep cervical fascia and the tip is placed adjacent to the plexus.~Following negative aspiration, 1 mL of local anesthetic is injected to confirm the proper injection site. The remainder of the local anesthetic (5ml) is administered to envelop the plexus.
Study NCT05476003 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided Bilateral superficial cervical plexus block
Description: This nerve block is typically performed in the supine or semi-sitting position, with the head turned slightly away from the side to be blocked to facilitate operator access.~Under strict aseptic condition, the linear ultrasound transducer should be placed on the lateral neck, overlying the sternocleidomastoid muscle at the level of its midpoint (approximately the level of the cricoid cartilage). Once the sternocleidomastoid muscle has been identified, the transducer is moved posteriorly until the tapering posterior edge is positioned in the middle of the screen.~Once the plexus has been identified and using In-Plane approach, the needle is passed from medial to lateral through the skin, platysma and investing layer of deep cervical fascia and the tip is placed adjacent to the plexus.~Following negative aspiration, 1 mL of local anesthetic is injected to confirm the proper injection site. The remainder of the local anesthetic (5ml) is administered to envelop the plexus.
Study NCT05476003 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Midazolam
Description: All patients will be premedicated with Midazolam (0.02mg/Kg).
Study NCT05476003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: All patients will be premedicated with Midazolam (0.02mg/Kg).
Study NCT05582538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: 240mg orally BD (dose level 0) on days -6 to 0 prior to day 1 cycle 1 and then on days 22 to 28 of cycle 1 and every subsequent cycle
Study NCT05582538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg i.v. day 1 (q28)
Study NCT05582538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 100mg/m2 i.v. day 1,8,15 (q28)
Study NCT04793165 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-hybrid closed-loop system with ARG algorithm
Description: To assess efficacy and safety of non-Hybrid Closed-loop System, without CHO counting
Study NCT06539936 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glide
Description: Glide is a myoelectric prosthesis control strategy which enables multifunctional control using a limited set of input EMG signals (as few as two). The Glide control strategy uses the relative contributions of multiple electrode inputs to create a virtual cursor, calculated from a vector summation of multiple EMG channels, to select the type and speed of a movement from a circular map.
Study NCT06539936 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct Control
Description: Direct Control (DC) is the most common method of control for powered prostheses, which directly links the activity recorded from a single electromyography (EMG) electrode to a prosthesis action. Typically, a pair of EMG electrodes are placed over a pair of agonist/antagonist muscle groups to operate a single DOF (e.g., for transradial amputees the flexor muscles in the forearm may be mapped to the prosthetic hand closing and the forearm extensor muscles mapped to hand opening).
Study NCT06266494 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long-Acting silver dressings
Description: Mepilex Transfer Ag
Study NCT04757012 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: calinange
Description: calinange
Study NCT05217732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-7101A
Description: tablet
Study NCT05217732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet
Study NCT06266494 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aloe Vera
Description: Dermaid Aloe Vera
Study NCT06266494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Description: 1500mg IV dose
Study NCT05919797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone-Bupropion Combination
Description: Participants receive 28 weeks of naltrexone-bupropion weight loss medication during phase two of this study.
Study NCT06237283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early shower
Description: Start shower after drain removal
Study NCT04837638 — intervention group
Intervention type: BEHAVIORAL
Intervention: Diet
Description: No intervention. Cross-section assessment of the relationship between diet, medication, lifestyle and coronary artery calcification.
Study NCT05090501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Circuit Training
Description: The participants will execute a 12-exercise High Intensity Circuit Training protocol. Each exercise will have an active part taking 30 seconds, in which exercisers are encouraged to do as many repetitions as possible, and a resting part taking 10 seconds in which the participants rest and are informed of the next exercise. Before and after the 12-exercise routine, the participants rate their affect, arousal and perceived exertion, while using a heart rate monitor and two IMU sensors on their arms and legs.
Study NCT05760066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training Preconditioning
Description: Resistance training prior to disuse-induced atrophy followed by another period of resistance training
Study NCT05760066 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Activities of daily living prior to disuse-induced atrophy followed by a period of resistance training
Study NCT04957602 — intervention group
Intervention type: OTHER
Intervention: Blood collection
Description: Blood collection (4\*10ml) before treatment initiation and after the first evaluation (usually 3-4 months after treatment initiation).
Study NCT06485232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Universal BCMA CAR-T
Description: Universal BCMA CAR-T
Study NCT06485232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Universal CD19 CAR-T
Description: Universal CD19 CAR-T
Study NCT04924192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3616 capsules
Description: A CDK4/6 kinase inhibitor
Study NCT04924192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride capsules
Description: A multi-target receptor tyrosine kinase inhibitor
Study NCT04924192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride for Injection
Description: An inhibitor of DNA topoisomerase Ⅰ
Study NCT06375954 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic biliary drainage
Description: Decompression of the bile duct by endoscopic aproach.
Study NCT06375954 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic biliary drainage
Description: Decompression of the bile duct by endoscopic aproach.
Study NCT06375954 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-expandable metallic stent (SEMS)
Description: Self-expandable metallic stent (SEMS) deployment:~* Covering: Uncovered or Partially Covered. Non covered if gallbladder is present.~* Size: 10x40mm or 10x60mm or 10x80mm.
Study NCT06375954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)
Description: Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment:~* LAMS size: 6x8mm or 8x8mm. Consider 10x10mm if bile duct > 18mm.~* DPPS size: 7Fr x 3-7cm.
Study NCT06617013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinuation of GERD therapy
Description: GERD therapy will be discontinued at time of enrollment.